Preexisting Diabetes Elevates Risk of Local and Systemic Complications in Acute Pancreatitis: Systematic Review and Meta-analysis. by Mikó, Alexandra et al.
D
ow
nloaded
from
http://journals.lw
w
.com
/pancreasjournalby
B
hD
M
f5eP
H
K
bH
4TTIm
qenV
H
0e3gbzxI4t7G
0N
lG
pd3V
cIN
0d6oyfIg3tLG
3tnnD
0cE
snLN
aZ42lk=
on
08/17/2018
Downloadedfromhttp://journals.lww.com/pancreasjournalbyBhDMf5ePHKbH4TTImqenVH0e3gbzxI4t7G0NlGpd3VcIN0d6oyfIg3tLG3tnnD0cEsnLNaZ42lk=on08/17/2018
Preexisting Diabetes Elevates Risk of Local and Systemic
Complications in Acute Pancreatitis
Systematic Review and Meta-analysis
Alexandra Mikó, MD, PhD,* Nelli Farkas, PhD,*† András Garami, MD, PhD,* Imre Szabó, MD, PhD,‡
Áron Vincze, MD, PhD,‡ Gábor Veres, MD, PhD, DSc,§ Judit Bajor, MD,‡ Hussain Alizadeh, MD, PhD,||
Zoltán Rakonczay, Jr, MD, PhD, DSc,¶ Éva Vigh, MD, PhD,#** Katalin Márta, MD,* Zoltán Kiss, MD,§
Péter Hegyi, MD, PhD, DSc,*††‡‡ and László Czakó, MD, PhD, DSc¶
Abstract: The prevalence of diabetes mellitus (DM) and acute pancreati-
tis (AP) increases continuously, therefore, to understand the effects of
preexisting diabetes on AP is crucially needed. Here, we performed a sys-
tematic review and meta-analysis in which AP patients including DM and
non-DM groups were sorted. Several outcome parameters were analyzed,
and the odds ratio (OR) and standardized mean difference with 95% confi-
dence intervals (CIs) were calculated.
We found 1417 articles, of which 9 articles involving 354,880 patients
were analyzed. More complications were seen in diabetic patients than in
non-DM patients (OR, 1.553 [95%CI, 1.266–1.904]; P < 0.001). Intensive
care unit admission (OR, 1.799 [95% CI, 1.442–2.243]; P < 0.001) and re-
nal failure (OR, 1.585 [95% CI, 1.278–1.966]; P < 0.001) were more fre-
quent in DM patients. There was a tendency of higher mortality and local
complications (OR, 1.276 [95% CI, 0.991–1.643]; P = 0.059; and OR,
1.267 [95% CI, 0.964–1.659]; P = 0.090, respectively) in preexisting
DM. Length of hospitalization was longer in DM patients (standardized
mean difference, 0.217 [95% CI, 0.075–0.360]; P = 0.003). Preexisting
DMnegatively influences the outcome of AP and increases the risk of renal
failure, local complications, and mortality.
KeyWords: acute pancreatitis, complications, diabetesmellitus, mortality,
length of hospitalization
(Pancreas 2018;47: 917–923)
A cute pancreatitis (AP) is a severe inflammatory conditionwith increasing incidence and hospitalization worldwide.1,2
Acute pancreatitis has a variable severity ranging from mild and
self-limited to severe and fatal. The mortality of the disease ranges
approximately from 2 to 5% and depends on the development of
organ failure and local complications, which are summarized in the
revised 2012 Atlanta classification.3 The major etiological factors
are gallstones and alcohol intake,1 but hypertriglyceridemia and in-
take of certain medications may also be present in the background.
The global prevalence of diabetes among adults doubled be-
tween 1980 and 2014.4 The relationship between AP and diabetes
mellitus (DM) is complex. Acute pancreatitis may result in DM.5
On the other hand, patients with type 2 (T2) DM had an elevated
risk of AP,6–10 and the risk of AP in diabetic patients can be re-
duced with appropriate glycemic control.11 Furthermore, DM pa-
tients tend to develop hypertriglyceridemia and gallstones, both of
which may lead to AP.12,13 Hyperglycemia was demonstrated to
be closely correlated with poor outcomes of morbidity and mortal-
ity in critically ill patients.14 Many patients with T2DM have co-
morbid conditions (eg, heart failure, renal disease, liver disease,
and obesity), which may increase the risk of severe AP and can
be strong predictors of early death from AP.15,16 Moreover, diabetic
comorbidities require the use of medications that have been associ-
ated with pancreatitis. Incretin use in the treatment of T2DM has
been investigated in several meta-analyses of the risk of AP.17–21
Experimental studies clearly suggest that preexisting diabe-
tes deteriorates the outcome of AP. Zechner et al22 showed that di-
abetes significantly raises the plasma interleukin 6 concentration
and further reduces the number of lymphocytes during AP; diabetes
thus exacerbates pancreatitis-induced systemic inflammation. Other
studies have also demonstrated that diabetes increases pancreatic fi-
brosis23,24 and decreases pancreatic regeneration.25–27 Importantly,
cholecystokinin-promoted pancreatic regeneration was also impaired
in diabetic rats after the induction of experimental pancreatitis.28
Unfortunately, little human data are available on the effect of
preexisting DM or the complications of AP. No systematic reviews
or meta-analyses are available to summarize our knowledge of the
effects of preexisting diabetes on the outcome of AP.
In this study, we therefore aimed to demonstrate the influence
of preexisting DM on the outcomes of AP, including mortality,
length of hospitalization (LOH), incidence of organ failure, and in-
tensive care unit (ICU) admission in a large number of patients by
using detailed meta-analyses of the data available in the literature.
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MATERIALS AND METHODS
Search Strategy
This study was conducted according to the principles in the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement29 (Supplementary Table 1, http://links.
lww.com/MPA/A663) and was registered in the PROSPERO
registry (under registration number CRD42016053207). Our meta-
analysis was based on the patient, intervention, comparison, and
outcome (PICO) format (P, patients suffering from AP; I, diabetic
patients; C, nondiabetic patients; O, mortality, LOH, organ failure,
ICU admission). A systematic search was made in 3 databases,
Pubmed, Embase, and the Cochrane Library, using the following
terms: acute pancreatitis and diabetes mellitus. The search was
limited to human data and to full-text English articles. The exact
search terms in Pubmed were as follows: (acute[all fields] and
(pancreatitis[MeSH terms] or pancreatitis[all fields])) and (dia-
betes mellitus[MeSH terms] or (diabetes[all fields] and mellitus
[all fields]) or diabetes mellitus[all fields]) and (humans[MeSH
terms] and English[lang]). The database search was conducted
up to March 8, 2017. The duplicates were removed using the
EndNote X7 reference manager software (Clarivate Analytics,
Philadelphia, Penn).
Study Selection
The studies were selected separately by two investigators (A.M.
and L.C.). Disagreements were resolved by consulting a third re-
viewer (P.H.). Clinical studies were eligible provided that they re-
ported the data for adult patients suffering from AP separately for
diabetic and nondiabetic patients. Information on the outcome of
pancreatitis (mortality, organ failure, LOH, and admission to
ICU) was searched for manually (Supplementary Table 2,
http://links.lww.com/MPA/A663). The reference lists in the ar-
ticles obtained were also checked, but no additional eligible arti-
cles were found.
Data Extraction
For statistical analysis, mortality data were calculated by
number of patients30,31; local complications32 and renal failure
data33 were expressed as percentages. The data for Supplementary
Table 2 (http://links.lww.com/MPA/A663) from Mole et al34 were
computed, and the percentage for ICU admission was calculated
for the DM and non-DM groups. Kikuta et al30 presented graphs
on organ failures in DM and non-DM groups each day in the first
72 hours. These data were confirmed by the investigators, and an
average value was calculated from data for 3 days. Nawaz et al35
only presented the median for LOH. The interquartile range for
these data was requested for statistical analysis.
The basic characteristics of the 9 eligible articles included in
the meta-analysis are shown in Table 1.
Data Synthesis and Analysis
All meta-analysis calculations were made with Comprehensive
Meta-Analysis software version 3 (Biostat, Inc., Englewood, NJ)
using the random effects model (DerSimonian-Laird method39).
Odds ratios (OR) and 95% confidence intervals (CIs) were calcu-
lated for binary outcomes. In the case of LOH, standardized mean
difference with 95% CI was calculated to compare mean data. We
used the conversion method by Hozo et al40 because only the me-
dian and interquartile range were provided in some studies.31,35,37
All analyses were 2-tailed, with an α value of 0.05.
Heterogeneity was tested using Cochrane Q and I2 statistics.
Based on the Cochrane Handbook, I2 = 100%  (Q − df )/Q rep-
resents the magnitude of the heterogeneity (moderate, 30%–60%;
substantial, 50%–90%; considerable, 75%–100%).41
The results from 4 or more studies were displayed graphi-
cally using forest plots. These outcomes are mortality, LOH, and
complications. Results were also weighted based on the number
of patients studied in the articles. To assess required information
size and to estimate the robustness of our conclusions, we con-
ducted a trial sequential analysis (TSA; with TSA tool from Co-
penhagen Trial Unit, Center for Clinical Intervention Research,
TABLE 1. Description of the Studies Included in the Meta-analysis
Study Country Study Type Years of Study Group Sample Size Age,* y
Huh et al, 201636 Korea Retrospective 2013–2015 DM 54 62.5
Non-DM 147 58.3
Kikuta et al, 201530 Japan Retrospective 2007 DM 250 60.3
Non-DM 1704 59.1
Kumar et al, 201533 India Retrospective 2011–2012 DM 34 ―
Non-DM 48 ―
Méndez-Bailón et al, 201537 Spain Retrospective 2001–2011 DM 42,009 69.6
Non-DM 240,340 62.1
Mole et al, 201634 Scotland Retrospective 2009–2012 DM 398 ―
Non-DM 1655 ―
Nawaz et al, 201535 United States Retrospective/prospective 1996–2005 DM 1349 63
Non-DM 6050 56
Shen et al, 201231 Taiwan Retrospective 2000–2009 DM 18,990 58
Non-DM 37,980 58
Shen et al, 201232 Taiwan Prospective No data DM 2165 ―
Non-DM 1389 ―
Zhao et al, 201238 China Retrospective 2009–2010 DM 40 57.2
Non-DM 278 44.3
*Data expressed as either mean or median.
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Denmark; version 0.9 beta, www.ctu.dk/tsa) and a sensitivity
analysis. The required information size calculation was based on
the assumption of a 10% relative risk reduction, and we adjusted
all analysis for heterogeneity (diversity adjustment). The TSA
monitoring boundaries were built based on a risk for a type I
error of 5% and a type II error of 20%. If a TSA monitoring
boundary is crossed with a Z-curve before the required
information size is reached, robust evidence might have been
confirmed and further trials are unnecessary. Therefore, more
trials are needed in this field. With sensitivity analysis, we can
assess whether altering any of the assumptions may lead to
different final interpretations or conclusions.42
Quality of Studies and Risk of Bias
Because of the low number of articles, publication bias was
obtained by visual inspection of the funnel plots. The
Newcastle-Ottawa scale43 was used for a quality assessment of
nonrandomized cohort studies. The selection, comparability, and
outcome data were assessed with the star system based on 7 items
(Supplementary Tables 3–4, http://links.lww.com/MPA/A663):
high-quality items carrying a low risk of bias were assigned one
star, whereas low-quality items carrying a high or unknown risk
of bias received no stars. Selection consisted of 4 items, with arti-
cles earning 2 stars for comparability and only adequacy of
follow-up being rated at outcome. Assessment of outcome and
length of follow-up were not rated because most of the articles
were retrospective. We assigned a star for responsiveness of study
population if all of the AP patients with or without DM were in-
cluded, but no stars were given whenever selection criteria were
applied. Low risk of bias was assessed if AP diagnosis was
ascertained by 2 of 3 criteria (elevation of serum amylase and/or
lipase activity at least 3 times higher than the upper normal limit,
presence of abdominal pain, and inflammation detected with abdom-
inal ultrasound and/or computed tomography) and if the standard
definition of preexisting DM was applied, whereas the inclusion
of newly diagnosed DM based on elevated HbA1c was also accept-
able.44 Diabetes mellitus and non-DM patients were compared
based on age and body mass index because the negative influence
of obesity is well known in AP patients.45 If there was a follow-
up, the adequate number of patientswas screened for complications.
RESULTS
Study Selection
Database searches produced a total of 1417 articles (Embase,
759; PubMed, 590; Cochrane, 68). The flow chart diagram (Fig. 1)
shows the strategy for article selection. Studies used in our meta-
analysis were dated from 1948 toMarch 2017. After removal of du-
plicates, 1119 unique records remained. Following initial screening
based on titles and abstracts, case reports and records with data on
children were excluded; 52 articles were finally retrieved and
screened. A further 43 articles were excluded: 34 because the
main outcome was the risk of development of AP, 5 because of
the inappropriate classification of values (there were no DM and
non-DM groups), 1 by reason of missing numerical outcome data,
2 with only late outcome data (pancreatic exocrine or endocrine
insufficiency), and 1 in which not all of the patients had AP.
The remaining 930–38 articles were included in the meta-analysis
(Table 1). They consisted of 354,880 patients, 65,289 of whom
had preexisting DM as a comorbidity.
FIGURE 1. Flowchart for the study selection procedure.
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Complications
The rate of complications in the 2 AP groups was analyzed
first. Overall, based on 7 articles, more complications were seen
in DM patients than in non-DM patients (OR, 1.553 [95% CI,
1.266–1.904]; P < 0.001) (Fig. 2).
A subgroup analysis was conducted to detect which types of
complications are most frequent in DM. In the case of preexisting
DM, significantly more ICU admissions (OR, 1.799 [95% CI,
1.442–2.243]; P < 0.001) and renal failure (OR, 1.585 [95% CI,
1.278–1.966]; P < 0.001) were seen than in non-DM patients. Di-
abetic patients more often develop local complications (OR, 1.276
[95% CI, 0.991–1.643]; P = 0.059), but the difference did not
reach statistical significance. No differences were found in cardio-
vascular (OR, 0.942 [95%CI, 0.722–1.23]; P = 0.661), neurological,
and respiratory complications (OR, 1.060 [95% CI, 0.833–1.349];
P = 0.636) (Fig. 3).
Mortality and LOH
Among the 9 studies, only 6 included the mortality data for
AP patients. A tendency of higher AP mortality was observed in
DM patients as compared with non-DM patients (OR, 1.265
[95% CI, 0.964–1.659]; P = 0.090) (Fig. 4). Length of hospital-
ization was longer in DM patients than in non-DM patients
based on 5 articles (standardized mean difference, 0.217 [95% CI,
0.075–0.360]; P = 0.003) (Fig. 5).
Heterogeneity and Quality Assessment of Data
High heterogeneity was detected for overall complications
(Q = 25.12; DF = 6; I2 = 76.11%; P < 0.001), renal failure
(Q = 10.32; DF = 3; I2 = 70.96%; P = 0.016), mortality (Q = 49.2;
DF = 5; I2 = 89.84%; P < 0.001) and LOH (Q = 414.74; DF = 4;
I2 = 99.03%;P < 0.001), whereas lower heterogeneity was observed
for ICU admission (Q = 4.43; DF = 2; I2 = 54.84%; P = 0.11) and
local complications (Q = 1.77; DF = 2; I2 = 0%; P = 0.41). To eval-
uate publication bias, we only made a visual assessment of the fun-
nel plot (Supplementary Fig. 1, http://links.lww.com/MPA/A677)
because we were only able to include 9 studies in our meta-
analysis. According to the Cochrane Handbook,41 “tests for funnel
plot asymmetry should be used only when there are at least 10 stud-
ies included in the meta-analysis, because when there are fewer
FIGURE2. Forest plot representing the differences in complications inDMand non-DMpatients suffering fromAP. Size of squares for risk ratio
reflects weight of trial in pooled analysis. Horizontal bars represent 95%CIs. Single, only 1 complication is available; 2+, more complications
are available; a, cardiovascular; b, respiratory; c, renal; d, local; e, intensive care unit admission; f, neurological.
FIGURE3. Forest plot representing detailed differences in several types of complications inDMand non-DMpatients suffering fromAP. Size of
squares for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95% CIs.
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studies the power of the tests is too low to distinguish chance from
real asymmetry.” Articles received between 1 and 5 stars out of the
maximum 7 stars on the Newcastle-Ottawa scale (Supplementary
Table 4, http://links.lww.com/MPA/A663). A high risk of bias
was identified in terms of the representativeness of the study pop-
ulation because AP patients were selected in most of the articles
(Supplementary Fig. 2, http://links.lww.com/MPA/A678). The
percentage of unclear risk of bias was 77.8% in the presence of
outcome of interest (Supplementary Fig. 2, http://links.lww.com/
MPA/A678), but cardiovascular, renal, and respiratory complica-
tions were available in only 3 or 4 articles. Body mass index data
were available in only 3 articles, but unfortunately, a statistical dif-
ference was observed between DM and non-DM groups. Two ar-
ticles earned only 1 star,32,35 whereas 1 article received 5 stars38
(Supplementary Table 4, http://links.lww.com/MPA/A663).
Sensitivity analysis showed no significant difference in
overall and detailed complications and LOH (Supplementary
Figs. 3A, B, D, http://links.lww.com/MPA/A679), whereas if we
remove theMéndez-Bailon37 and Shen et al31 articles with respect
to mortality, OR for mortality would change significantly from
pooled OR (2.152 [95% CI, 1.063–4.358], P = 0.033 and 2.157
[95% CI, 1.165; 3.995], P = 0.014, respectively) (Supplementary
Fig. 3C, http://links.lww.com/MPA/A679). Both articles involve a
high number of patients and a longer follow-up time, but both ar-
ticles contain data on a large patient population. We therefore in-
cluded them in our meta-analysis.
Trial sequential analysis showed that in combinations and mor-
tality the information size to achieve is 2,903,700, and these studies
do not reach this yet (Supplementary Figs. 4A, B, http://links.lww.
com/MPA/A680). With regard to LOH, studies reached the
appropriate information size (301,416) (Supplementary Fig.
4C, http://links.lww.com/MPA/A680).
DISCUSSION AND CONCLUSIONS
In this meta-analysis, we investigated the influence of preexisting
DM on different outcome parameters in AP patients. With regard
to overall complications, we found significantly more complica-
tions in DM groups than in non-DM groups (Fig. 2), and higher
rates of renal failure and ICU admission were also observed
(Fig. 3). One quarter to half of the patients diagnosed with DM
might develop chronic kidney disease, thus increasing mortality
of DM.46 The development of renal failure determines the severity
of AP according to the revised 2012 Atlanta Classification,3 and it
raises the mortality of AP.47 The mechanism for renal failure during
AP is not yet completely understood, but it has been shown that
injury due to inflammatory mediators, cytokines, transcription
factors, microcirculation changes, and apoptosis are important
pathogenic factors.48 Development of renal failure increased the
mortality of AP, suggesting that it has detrimental effects on pa-
tients with preexisting DM. The data in our meta-analysis indi-
cated a tendency of higher mortality in DM patients (Fig. 4). It
must be noted that there are data that contradict our findings. In-
tensive care unit mortality only grew significantly with higher
mean blood glucose concentration in non-DM patients but not
in DM patients.14,49 For example, Graham et al50 showed that crit-
ically ill patients with DM do not experience higher mortality
compared with that seen in patients without DM. This may be ex-
plained with the beneficial antioxidant and anti-inflammatory ef-
fects of exogenous insulin used for treating hyperglycemia in
FIGURE 4. Forest plot representing the differences in mortality in DM and non-DM patients suffering from AP. Size of squares for risk ratio
reflects weight of trial in pooled analysis. Horizontal bars represent 95% CIs.
FIGURE 5. Forest plot representing the differences in LOH in DM and non-DM patients suffering from AP. Size of squares for the difference
in standardized mean values reflects weight of trial in pooled analysis. Horizontal bars represent 95% CIs.
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DM.51,52 Insulin acts on the suppression of innate immune mech-
anisms and transcription factors NF-ĸB and Egr-1.52 With regard
to the local complications in our analyses, DM patients tend to de-
velop local complications more often. This is most probably due
to damage to the endocrine-exocrine axis, which was discussed
in detail in the background section.
Based on pooled data, diabetic AP patients spendmore time in
hospital (Fig. 5). This can be explained by the more intense sys-
temic inflammatory response, more frequent complications, slower
recovery, and settlement of glucose homeostasis in DM patients.
The OR calculated for mortality and LOH data in Zhao et al38 differ
from those in the other studies. This is clear from the mortality and
LOH data, but we did not remove it because this article received the
highest points on the Newcastle-Ottawa scale and the sensitivity
analysis showed no difference. In cases of cardiovascular and re-
spiratory complications, no difference was observed based on
diabetic status.
Several studies have demonstrated that obesity may worsen
the clinical outcome of AP.45,53,54 Diabetes mellitus patients tend
to have higher body mass index, but unfortunately this data was
only represented in a few articles and therefore was not suitable
for data analysis.
There are several limitations of this study; therefore, the results
of this meta-analysis should be regarded with caution. The greatest
limitation is the low number of eligible articles included, thus causing
higher heterogeneity. Second, the lowamount of extracted data causes
further difficulties. In addition, this meta-analysis includesmostly ret-
rospective cohort studies. Five of 9 articles report patients from East
Asia (Taiwan, Japan, Korea, and China), and only 2 present data on
patients with severe AP. The Newcastle-Ottawa scale star count is un-
fortunately low because the data were incomplete. Trial sequential
analysis showed that no sufficient data are available on this topic
and further investigations are needed to show the connection be-
tween DM and complications of AP. However, despite the limita-
tions, a notable advantage of our analysis is that it covers articles
with data on patients from the last 20 years.
In summary, our meta-analysis highlights the crucial impor-
tance of the diagnosis of DM in AP patients. It is therefore highly
recommended that a diagnosis be made by measuring fasting glu-
cose and HbA1c levels on admission. The increased risk for renal
failure warrants more frequent measurements of renal function pa-
rameters in AP patients also suffering from DM. Nevertheless, the
high frequency of the cooccurrence of DM and AP patients sug-
gests that further prospective high-quality cohort studies are nec-
essary to understand the true link between AP and preexisting
DM. First, an observational clinical trial would help us to under-
stand the differences between the effects of (1) untreated preexisting
diabetes with high HbA1c level and (2) well controlled, previ-
ously diagnosed diabetes. Second, the local mechanisms behind
the harmful effects of preexisting diabetes need in depth scrutiny.
Therefore, another trial should be performed in which the levels of
insulin, C-peptide, and glucagon are measured in patients with AP
and DM. It is needless to say that further interventional studies
should be performed to identify the best treatment options of dia-
betes during AP.
In conclusion, our systematic review andmeta-analysis clearly
shows that preexisting DM negatively influences AP outcomes by
raising the incidence of renal failure, ICU admission, and LOH
and leads to a tendency of higher mortality.
ACKNOWLEDGMENTS
The present scientific contribution is dedicated to the 650th
anniversary of the founding of the University of Pécs, Hungary.
REFERENCES
1. Rebours V. [Acute pancreatitis: an overview of the management]. [Article
in French]. Rev Med Interne. 2014;35:649–655.
2. Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States
hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol.
2007;17:491–497.
3. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute
pancreatitis—2012: revision of the Atlanta classification and definitions by
international consensus. Gut. 2013;62:102–111.
4. WHO Press, Global report on diabetes. Geneva, Switzerland. 2016.
5. Vujasinovic M, Tepes B, Makuc J, et al. Pancreatic exocrine insufficiency,
diabetes mellitus and serum nutritional markers after acute pancreatitis.
World J Gastroenterol. 2014;20:18432–18438.
6. Xue Y, Sheng Y, Dai H, et al. Risk of development of acute pancreatitis
with pre-existing diabetes: a meta-analysis. Eur J Gastroenterol Hepatol.
2012;24:1092–1098.
7. Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of
acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:
225–231.
8. Urushihara H, TaketsunaM, Liu Y, et al. Increased risk of acute pancreatitis
in patients with type 2 diabetes: an observational study using a Japanese
hospital database. PloS One. 2012;7:e53224.
9. GirmanCJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have
higher risk for acute pancreatitis compared with those without diabetes.
Diabetes Obes Metab. 2010;12:766–771.
10. Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2
diabetes and risk reduction on anti-diabetic drugs: a population-based
cohort study in taiwan. Am J Gastroenterol. 2011;106:1697–1704.
11. Gonzalez-Perez A, Schlienger RG, García Rodríguez LA. Acute
pancreatitis in association with type 2 diabetes and antidiabetic drugs:
a population-based cohort study. Diabetes Care. 2010;33:2580–2585.
12. Aune D, Vatten LJ. Diabetes mellitus and the risk of gallbladder disease:
a systematic review and meta-analysis of prospective studies. J Diabetes
Complications. 2016;30:368–373.
13. Laakso M. Lipid disorders in type 2 diabetes. Endocrinol Nutr. 2009;
56 Suppl 4:43–45.
14. Egi M, Bellomo R, Stachowski E, et al. Blood glucose concentration and
outcome of critical illness: the impact of diabetes. Crit Care Med. 2008;36:
2249–2255.
15. Frey C, Zhou H, Harvey D, et al. Co-morbidity is a strong predictor of early
death and multi-organ system failure among patients with acute
pancreatitis. J Gastrointest Surg. 2007;11:733–742.
16. Premkumar R, Phillips AR, Petrov MS, et al. The clinical relevance of
obesity in acute pancreatitis: targeted systematic reviews. Pancreatology.
2015;15:25–33.
17. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based
therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes
mellitus: a population-based matched case-control study. JAMA Intern
Med. 2013;173:534–539.
18. Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk
of acute and chronic pancreatitis: a population-based cohort study.Diabetes
Obes Metab. 2017;19:401–411.
19. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in
patients with type 2 diabetes mellitus: systematic review and meta-analysis
of randomised and non-randomised studies. BMJ. 2014;348:g2366.
20. Goodger RL, Asrani VM, Windsor JA, et al. Impact of metabolic
comorbidities on outcomes of patients with acute pancreatitis: a scoping
review. Panminerva Med. 2016;58:86–93.
21. Monami M, Dicembrini I, Nardini C, et al. Glucagon-like peptide-1
receptor agonists and pancreatitis: a meta-analysis of randomized clinical
trials. Diabetes Res Clin Pract. 2014;103:269–275.
Mikó et al Pancreas • Volume 47, Number 8, September 2018
922 www.pancreasjournal.com © 2018 Wolters Kluwer Health, Inc. All rights reserved.
22. Zechner D, Spitzner M, Müller-Graff T, et al. Diabetes increases
pancreatitis induced systemic inflammation but has little effect on
inflammation and cell death in the lung. Int J Exp Pathol. 2014;95:
411–417.
23. Zechner D, Knapp N, Bobrowski A, et al. Diabetes increases pancreatic
fibrosis during chronic inflammation.Exp BiolMed (Maywood). 2014;239:
670–676.
24. Zechner D, Spitzner M, Bobrowski A, et al. Diabetes aggravates acute
pancreatitis and inhibits pancreas regeneration inmice.Diabetologia. 2012;
55:1526–1534.
25. Hegyi P, Takács T, Tiszlavicz L, et al. Recovery of exocrine pancreas six
months following pancreatitis induction with L-arginine in
streptozotocin-diabetic rats. J Physiol Paris. 2000;94:51–55.
26. Hegyi P, Czako L, Takacs T, et al. Pancreatic secretory responses in
L-arginine-induced pancreatitis: comparison of diabetic and nondiabetic
rats. Pancreas. 1999;19:167–174.
27. Hegyi P, Rakonczay Z Jr, Sari R, et al. Insulin is necessary for the
hypertrophic effect of cholecystokinin-octapeptide following acute
necrotizing experimental pancreatitis.World J Gastroenterol. 2004;10:
2275–2277.
28. Takács T, Hegyi P, Jármay K, et al. Cholecystokinin fails to promote
pancreatic regeneration in diabetic rats following the induction of
experimental pancreatitis. Pharmacol Res. 2001;44:363–372.
29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
2009;6:e1000097.
30. Kikuta K, Masamune A, Shimosegawa T. Impaired glucose tolerance in
acute pancreatitis. World J Gastroenterol. 2015;21:7367–7374.
31. Shen HN, Lu CL, Li CY. Effect of diabetes on severity and hospital
mortality in patients with acute pancreatitis: a national population-based
study. Diabetes Care. 2012;35:1061–1066.
32. Shen HN, Chang YH, Chen HF, et al. Increased risk of severe acute
pancreatitis in patients with diabetes. Diabet Med. 2012;29:1419–1424.
33. Kumar R, Pahwa N, Jain N. Acute kidney injury in severe acute
pancreatitis: an experience from a tertiary care center. Saudi J Kidney Dis
Transpl. 2015;26:56–60.
34. Mole DJ, Gungabissoon U, Johnston P, et al. Identifying risk factors for
progression to critical care admission and death among individuals with
acute pancreatitis: a record linkage analysis of Scottish healthcare
databases. BMJ Open. 2016;6:e011474.
35. Nawaz H, O'Connell M, Papachristou GI, et al. Severity and natural
history of acute pancreatitis in diabetic patients. Pancreatology.
2015;15:247–252.
36. Huh JH, Jeon H, Park SM, et al. Diabetes mellitus is associated
with mortality in acute pancreatitis. J Clin Gastroenterol. 2018;52:
178–183.
37. Méndez-Bailón M, de Miguel Yanes JM, Jiménez-García R, et al.
National trends in incidence and outcomes of acute pancreatitis among
type 2 diabetics and non-diabetics in Spain (2001–2011). Pancreatology.
2015;15:64–70.
38. Zhao X, Chang Mei H, Chen L, et al. An increased level of haemoglobin
A1C predicts a poorer clinical outcome in patients with acute pancreatitis.
Clin Endocrinol (Oxf ). 2012;77:241–245.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials. 1986;7:177–188.
40. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from
the median, range, and the size of a sample. BMC Med Res Methodol.
2005;5:13.
41. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews
of Interventions. Version 5.1.0(updated 2011). The Cochrane
Collaboration; 2011. Available at: http://handbook.cochrane.org. Accessed
April 30, 2017.
42. Viel JF, Pobel D, Carre A. Incidence of leukaemia in young people
around the La Hague nuclear waste reprocessing plant: a sensitivity
analysis. Stat Med. 1995;14:2459–2472.
43. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS)
for assessing the quality of nonrandomised studies in meta-analyses. 2011.
Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Accessed April 30, 2017.
44. American Diabetes Association. Standards of medical care in
diabetes—2010. Diabetes Care. 2010;33(suppl 1):S11–S61.
45. Krishna SG, Hinton A, Oza V, et al. Morbid obesity is associated with
adverse clinical outcomes in acute pancreatitis: a propensity-matched study.
Am J Gastroenterol. 2015;110:1608–1619.
46. Radcliffe NJ, Seah JM, Clarke M, et al. Clinical predictive factors in
diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.
47. Lin HY, Lai JI, Lai YC, et al. Acute renal failure in severe pancreatitis:
a population-based study. Ups J Med Sci. 2011;116:155–159.
48. Zhang XP, Wang L, Zhou YF. The pathogenic mechanism of severe acute
pancreatitis complicated with renal injury: a review of current knowledge.
Dig Dis Sci. 2008;53:297–306.
49. Whitcomb BW, Pradhan EK, Pittas AG, et al. Impact of admission
hyperglycemia on hospital mortality in various intensive care unit
populations. Crit Care Med. 2005;33:2772–2777.
50. Graham BB, Keniston A, Gajic O, et al. Diabetes mellitus does not
adversely affect outcomes from a critical illness. Crit Care Med. 2010;38:
16–24.
51. Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and
acute ischemic stroke: a mechanistic justification for a trial of insulin
infusion therapy. Stroke. 2006;37:267–273.
52. Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect
and its clinical relevance. World J Diabetes. 2014;5:89–96.
53. Yoon SB, Choi MH, Lee IS, et al. Impact of body fat and muscle
distribution on severity of acute pancreatitis. Pancreatology. 2017;17:
188–193.
54. Jin Z, Xu L, Wang X, et al. Risk factors for worsening of acute pancreatitis
in patients admitted with mild acute pancreatitis.Med Sci Monit. 2017;23:
1026–1032.
Pancreas • Volume 47, Number 8, September 2018 Preexisting Diabetes and Acute Pancreatitis
© 2018 Wolters Kluwer Health, Inc. All rights reserved. www.pancreasjournal.com 923
